Conflicts of Interest on Vaccine Advisory Committees at Historic Lows

Vaccine advisory committees at the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have seen significant reductions in reported conflicts of interest over the past two decades. Despite this, recent moves to overhaul these committees have sparked concerns about industry influence. A new study published in JAMA finds that reported conflicts on these committees have been at historically low levels for years, contradicting claims of substantial conflict.

Key Takeaways:

• Reported conflicts of interest on the CDC's Advisory Committee on Immunization Practices (ACIP) fell from 43% in the early 2000s to an average of 6.2% between 2016 and 2024.
• The most common type of reported conflict was related to research grants, reflecting committee members' areas of expertise relevant to evaluating vaccine safety and effectiveness.
• Less than 1% of reported conflicts on both ACIP and the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) were related to personal income from vaccine makers, including consulting fees, stock, royalties, or ownership.
• The FDA took steps to curb conflicts of interest on its advisory committees, resulting in a significant reduction in reported conflicts.
• Corresponding to these changes, reported conflicts fell amid heightened scrutiny of industry ties in the early 2000s.
• The study's lead author notes that conflicts of interest on vaccine advisory committees have been at historically low levels for quite some time, suggesting that concerns about industry influence may be overstated.

Statistics:

• Average annual rates of reported financial conflicts of interest on ACIP: 43% (early 2000s) to 6.2% (2016-2024)
• Average annual rates of reported financial conflicts of interest on VRBPAC: 27% (early 2000s) to 1.9% (2016-2024)
• Less than 1% of reported conflicts on both committees were related to personal income from vaccine makers
• Less than 1% of reported conflicts on both committees were related to stock, royalties, or ownership from vaccine makers
• More than 99% of reported conflicts on both committees were related to research grants or other forms of industry support

Sources:

• University of Southern California Schaeffer Center for Health Policy & Economics
• JAMA (Journal of the American Medical Association)
• Centers for Disease Control and Prevention (CDC)
• Food and Drug Administration (FDA)
• Center for Science in the Public Interest